RCUS Latest Headlines

Arcus Biosciences Highlights Casdatifan Momentum in Call

at www.tipranks.com (Sat, 28-Feb 7:17 PM)

Wedbush Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)

at www.tipranks.com (Thu, 26-Feb 8:15 AM)

Arcus Biosciences GAAP EPS of -$0.89 beats by $0.14, revenue of $33M beats by $8.06M

at seekingalpha.com (Wed, 25-Feb 5:01 PM)

Here are the major earnings after the close Monday

at seekingalpha.com (Wed, 25-Feb 10:00 AM)

Wall Street Analysts Are Bullish on Top Healthcare Picks

at www.tipranks.com (Tue, 24-Feb 8:20 AM)

Buy Rating on Arcus Biosciences Driven by Best-in-Class Casdatifan Data in Renal Cell Carcinoma and Favorable Phase 3 Risk-Reward

at www.tipranks.com (Tue, 24-Feb 6:17 AM)

Arcus’s Lead HIF-2a Inhibitor Delivers Superior Late-Line RCC Efficacy, De-Risking PEAK-1 and Supporting Buy Rating

at www.tipranks.com (Tue, 24-Feb 5:45 AM)

Analysts’ Opinions Are Mixed on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), GeneDx Holdings (WGS) and Arcus Biosciences (RCUS)

at www.tipranks.com (Tue, 24-Feb 5:40 AM)

Arcus Halts STAR-221 Study, Sharpens Focus on Casdatifan and Next-Gen Inflammation Portfolio

Market Chameleon (Fri, 12-Dec 8:57 AM)